The session, Oral Semaglutide for Treatment of Obesity and Type 2 DiabetesResults from OASIS 1 and PIONEER PLUS Trials , can be viewed on-demand by registered meeting participants at ADA2023.org
Phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial weight reduction in participants with obesity, with some individuals achieving weight loss exceeding 20% of body weight over 48 weeks
But know this, for most people, nausea and other gastrointestinal side effects are more intense around the beginning of treatment
Please note that a credit or debit card is required to hold your appointment, but no charges will be made at the time of scheduling
In clinical trials, both exenatide and lixisenatide reduced body weight by 2.03.8 kg and reduced HbA 1c levels by 0.51.5% (5.51.6 mmol/mol) [23,24,25]